Cordyceps Sunshine Biotech Holdings (RAJAF) Notes Payables (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Notes Payables history runs 5 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Notes Payables rose 3.0% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (up 3.0% YoY), while the FY2025 annual figure was $4.0 million, up 3.0% from the prior year.
• Notes Payables was $4.0 million for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from $3.9 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $4.0 million in Q4 2025 to a low of $1.1 million in Q4 2021.
• Historically, Notes Payables has averaged $2.9 million across 4 years, with a median of $3.2 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Notes Payables increased 2.04% in 2021, then surged 49.44% in 2024.
• A 4-year view of Notes Payables shows it stood at $1.1 million in 2021, then surged by 133.5% to $2.6 million in 2023, then soared by 49.44% to $3.9 million in 2024, then climbed by 3.0% to $4.0 million in 2025.
• The last three Notes Payables figures came in at $4.0 million (Q4 2025), $3.9 million (Q4 2024), and $2.6 million (Q4 2023), per Business Quant data.